FDA Approved: EXJADE — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for Exjade (deferasirox) submitted by Novartis, resulting in changes to the product labeling as part of the supplemental…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Overload Due to Repeated Blood Transfusions

Drugs mentioned

• Exjade (deferasirox)

Snippet

SUPPL AP for EXJADE (DEFERASIROX)